{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T19:59:06Z","timestamp":1794081546539,"version":"4.8.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.antiviral.2020.104871","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T11:34:37Z","timestamp":1595590477000},"page":"104871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors"],"prefix":"10.1016","volume":"181","author":[{"given":"Xinyi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-4349","authenticated-orcid":false,"given":"Huizhen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104871_bib1","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/AAC.00777-10","article-title":"Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors","volume":"54","author":"Bae","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104871_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2013.06.029","article-title":"Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies","volume":"444","author":"Barnard","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2020.104871_bib3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"Bartenschlager","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104871_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039652","article-title":"HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors","volume":"7","author":"Cento","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2020.104871_bib5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s12879-019-4044-x","article-title":"Demographic characteristics of transfusion-transmitted infections among blood donors in China","volume":"19","author":"Chang","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104871_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.201300343","article-title":"Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity","volume":"8","author":"Coburn","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.antiviral.2020.104871_bib7","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Collaborators GBDCoD","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2020.104871_bib8","series-title":"Presented at AASLD","article-title":"Susceptibility to Voxilaprevir of NS3 resistance-associated substitutions and clinical isolates from direct-acting antiviral-experienced and -na\u00efve patients clinical isolates from direct-acting antiviral\u2013experienced and \u2013na\u00efve patients","author":"D-S","year":"2017"},{"key":"10.1016\/j.antiviral.2020.104871_bib9","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/jmv.24015","article-title":"Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches","volume":"86","author":"de Carvalho","year":"2014","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2020.104871_bib10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dkv403","article-title":"HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels","volume":"71","author":"Di Maio","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2020.104871_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jmv.25311","article-title":"The nationwide distribution and trends of hepatitis C virus genotypes in mainland China","volume":"91","author":"Du","year":"2019","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2020.104871_bib12","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.1016\/S0168-8278(12)61194-5","article-title":"1182 Characterization of HCV NS3 protease variants from patients enrolled in a 28-day phase 2a trial of ach-1625 daily dosing plus pegifn-alpha 2a\/rbv","volume":"56","author":"Fabrycki","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104871_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2015.04.009","article-title":"Grazoprevir\/elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent","volume":"63","author":"Forns","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104871_bib14","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104871_bib15","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1128\/JVI.00253-11","article-title":"Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052","volume":"85","author":"Fridell","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104871_bib16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104871_bib17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1-7 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2020.104871_bib18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1128\/AAC.01149-07","article-title":"Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system","volume":"52","author":"He","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104871_bib19","doi-asserted-by":"crossref","DOI":"10.1089\/mdr.2018.0360","article-title":"Comparison of naturally occurring resistance-associated substitutions between 2008 and 2016 in Chinese patients with chronic hepatitis C virus infection","volume":"25","author":"Huang","year":"2019","journal-title":"Microb. Drug Resist."},{"key":"10.1016\/j.antiviral.2020.104871_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155869","article-title":"Geno2pheno[HCV] - a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents","volume":"11","author":"Kalaghatgi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2020.104871_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034372","article-title":"Hepatitis C viral evolution in genotype 1 treatment-na\u00efve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials","volume":"7","author":"Kieffer","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104871_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159924","article-title":"Genetic barrier to direct acting antivirals in HCV sequences deposited in the European databank","volume":"11","author":"Kliemann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2020.104871_bib23","article-title":"In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of HCV NS5A","volume":"59","author":"Krishnan","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104871_bib24","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104871_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/bioinformatics\/bth485","article-title":"The Los Alamos hepatitis C sequence database","volume":"21","author":"Kuiken","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.antiviral.2020.104871_bib26","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104871_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","author":"Lawitz","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104871_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2020.104871_bib29","article-title":"Hepatitis C virus epidemiology and the impact of interferon-free hepatitis C virus therapy","author":"Lazarus","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.antiviral.2020.104871_bib30","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104871_bib31","article-title":"Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202)","volume":"58","author":"Lenz","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104871_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-8976-8_1","article-title":"Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus","volume":"1911","author":"Li","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2020.104871_bib33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2147\/IDR.S146595","article-title":"Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-na\u00efve hepatitis C genotype 1b-infected patients in western China","volume":"10","author":"Li","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.antiviral.2020.104871_bib34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s12072-018-9891-9","article-title":"Tolerable and curable treatment in HIV\/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China","volume":"12","author":"Li","year":"2018","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2020.104871_bib35","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14787210.2019.1675509","article-title":"How would China achieve WHO's target of eliminating HCV by 2030?","volume":"17","author":"Li","year":"2019","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.antiviral.2020.104871_bib36","article-title":"World-wide prevalence of substitutions in HCV genome associated with resistance to direct-acting antiviral agents","author":"Liu","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104871_bib37","article-title":"World-wide prevalence of substitutions in HCV genome associated with resistance to direct-acting antiviral agents","author":"Liu","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104871_bib38","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.10.019","article-title":"Randomized trial of daclatasvir and asunaprevir with or without PegIFN\/RBV for hepatitis C virus genotype 1 null responders","volume":"60","author":"Lok","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104871_bib39","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104871_bib40","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3389\/fmicb.2019.00535","article-title":"Subtype-specific prevalence of hepatitis C virus NS5A resistance associated substitutions in mainland China","volume":"10","author":"lu","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104871_bib41","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1128\/AAC.49.5.2059-2069.2005","article-title":"Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay","volume":"49","author":"Ludmerer","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104871_bib42","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1128\/AAC.01186-12","article-title":"Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104871_bib43","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.26388","article-title":"Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir","volume":"58","author":"McPhee","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104871_bib44","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104871_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02068-13","article-title":"Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin","volume":"58","author":"Murakami","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104871_bib46","doi-asserted-by":"crossref","first-page":"10031","DOI":"10.1021\/jm501291c","article-title":"Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition","volume":"57","author":"Nettles","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2020.104871_bib47","doi-asserted-by":"crossref","first-page":"34652","DOI":"10.1038\/srep34652","article-title":"Effects of resistance-associated NS5A mutations in hepatitis C virus on viral production and susceptibility to antiviral reagents","volume":"6","author":"Nitta","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2020.104871_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2015.1373","article-title":"Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV Co-infection","volume":"313","author":"Osinusi","year":"2015","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2020.104871_bib49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jviromet.2013.04.024","article-title":"A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir","volume":"193","author":"O'Boyle","year":"2013","journal-title":"J. Virol Methods"},{"key":"10.1016\/j.antiviral.2020.104871_bib50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.04.018","article-title":"Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a","volume":"99","author":"Palanisamy","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104871_bib51","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1743-422X-9-245","article-title":"Naturally occurring mutations to HCV protease inhibitors in treatment-nave patients","volume":"9","author":"Paolucci","year":"2012","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2020.104871_bib52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2020.104871_bib53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104871_bib54","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/jgh.13467","article-title":"Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study","volume":"32","author":"Rao","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104871_bib55","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104871_bib56","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104871_bib57","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2020.104871_bib58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist. Updates : reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.antiviral.2020.104871_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2015.1328","article-title":"Ombitasvir, Paritaprevir Co-dosed with Ritonavir, dasabuvir, and ribavirin for hepatitis C in patients Co-infected with HIV-1 A randomized trial","volume":"313","author":"Sulkowski","year":"2015","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2020.104871_bib60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104871_bib61","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients","volume":"50","author":"Susser","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104871_bib62","doi-asserted-by":"crossref","DOI":"10.1055\/s-0032-1323987","article-title":"Ultratiefe Pyrosequenz-Analyse (UDPS) von neu beschriebenen seltenen Resistenzvarianten der Hepatitis C Virus NS3 Protease bei Patienten, die mit Telaprevir oder Boceprevir behandelt wurden","volume":"50","author":"Susser","year":"2012","journal-title":"Z. Gastroenterol."},{"key":"10.1016\/j.antiviral.2020.104871_bib63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.antiviral.2007.11.010","article-title":"Characterization of resistance mutations against HCV ketoamide protease inhibitors","volume":"77","author":"Tong","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104871_bib64","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/jvh.12503","article-title":"NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naive subjects","volume":"23","author":"Vidal","year":"2016","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2020.104871_bib65","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/AAC.01874-12","article-title":"In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A","volume":"57","author":"Wang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104871_bib66","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","article-title":"Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104871_bib67","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s12072-018-9856-z","article-title":"Ledipasvir\/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study","volume":"12","author":"Wei","year":"2018","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2020.104871_bib68","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/AAC.02193-12","article-title":"Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104871_bib69","series-title":"Global Hepatitis Report 2017a","author":"World Health Organization Ghra","year":"2017"},{"key":"10.1016\/j.antiviral.2020.104871_bib70","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2147\/IDR.S218584","article-title":"Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide","volume":"12","author":"Wu","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.antiviral.2020.104871_bib71","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3851\/IMP3181","article-title":"Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir","volume":"23","author":"Wyles","year":"2018","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104871_bib72","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r\u2013ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104871_bib73","first-page":"163","article-title":"Grazoprevir\u2013elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial","author":"Zeuzem","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2020.104871_bib74","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104871_bib75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12985-017-0710-z","article-title":"Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution","volume":"14","author":"Zhang","year":"2017","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2020.104871_bib76","first-page":"213","article-title":"NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection","author":"Zhou","year":"2015","journal-title":"The Journal of infectious diseases"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:32:00Z","timestamp":1759062720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220302850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":76,"alternative-id":["S0166354220302850"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104871","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104871"}}